Table 1 Baseline characteristics of patients*
Characteristic | MA (N = 68) | LA (N = 69) | p value |
|---|---|---|---|
Age — yr | |||
Median | 65 | 65 | 0.734 |
Range | 47–85 | 50–80 | |
Sex — no. (%) | |||
Male | 55 (80.9) | 54 (78.2) | 0.833 |
Female | 13 (19.1) | 15 (21.7) | |
BMI — kg/m2 | 22.8 | 23.5 | 0.120 |
Tumor location — no. (%) | 0.658 | ||
Proximal third | 19 (27.9) | 15 (21.7) | |
Middle third | 31 (45.5) | 36 (52.1) | |
Distal third | 18 (26.4) | 18 (26.1) | |
Clinical T stage — no. (%) | 0.281 | ||
cT1 | 0 | 0 | |
cT2 | 8 (11.7) | 6 (8.6) | |
cT3 | 50 (73.5) | 58 (84.1) | |
cT4 | 10 (14.7) | 5 (7.2) | |
Clinical N stage — no. (%) | 0.821 | ||
N0 | 11 (16.1) | 14 (20.2) | |
N1 | 38 (55.8) | 40 (57.9) | |
N2 | 12 (17.6) | 10 (14.4) | |
N3 | 7 (10.2) | 5 (7.2) | |
WHO performance status score — no. (%)‖ | 0.851 | ||
0 | 49 (72.1) | 48 (69.6) | |
1 | 19 (27.9) | 21 (30.4) |